Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
76 of 180 long COVID-associated genes also linked to ME
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Subscribe To Our Newsletter & Stay Updated
